Why won't insurance or Medicare cover Wegovy?

Wegovy is approved for weight loss, and Medicare is barred by federal law from covering any drug used only for weight loss. Many commercial plans also exclude weight-loss drugs. Coverage is more likely when a patient also qualifies on cardiovascular grounds, since that is a heart-risk indication rather than weight loss alone.

Does Wegovy reduce heart risk?

Yes. Since March 2024, Wegovy is FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with both obesity and established heart disease. The approval was based on the SELECT trial, which found roughly a 20% reduction in major cardiovascular events versus placebo.

Can I use Wegovy if I don't have diabetes?

Yes. Wegovy is approved for chronic weight management based on BMI, not on having diabetes, so people without diabetes can qualify if they meet the BMI criteria. This is a key difference from Ozempic, which is approved specifically for type 2 diabetes rather than for weight loss.

Is compounded Wegovy still legal in 2026?

Generally no. Compounding a copy of a brand drug is mainly allowed during an official shortage. The FDA resolved the semaglutide injection shortage in February 2025, so broadly marketed compounded semaglutide lost its legal footing. Products sold as compounded or research-use-only are not FDA-verified for identity, dose, or sterility.

A pale-teal once-weekly weight-management injection pen resting on a clean white bathroom counter beside a tape measure under soft morning light.

Wegovy: The Weight-Loss Side of Semaglutide — Cost, Coverage & How It Differs from Ozempic

Q: How much does Wegovy cost per month in 2026?

Wegovy's list price is about $1,349 a month, but Novo Nordisk's cash-pay price is now around $349 a month standard, with a limited-time $199 introductory offer on the two lowest doses. People with commercial insurance that covers it may pay as little as about $25. Prices change frequently.

Q: What is the difference between Wegovy and Ozempic?

Both contain the same drug, semaglutide, made by Novo Nordisk, but Wegovy is approved and dosed for weight management at up to 2.4 mg, while Ozempic is approved and dosed for type 2 diabetes at up to 2 mg. That difference drives their pricing, insurance coverage, and which patients each is meant for.

Q: How much weight do people lose on Wegovy?

In the STEP 1 trial, adults on Wegovy 2.4 mg lost a mean of about 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, and most lost at least 5%. Individual results vary widely and depend on diet, activity, and how long someone stays on the drug.

Q: What is the Wegovy dose schedule?

Wegovy is a once-weekly injection that titrates over about 16 weeks through 0.25, 0.5, 1.0, and 1.7 mg before reaching the 2.4 mg maintenance dose, with each step lasting roughly four weeks. A higher 7.2 mg maintenance option also exists. The slow climb limits nausea and other digestive side effects.

Aurélie Rondon, Ph.D.Reviewed by Prof. Joanna Trylska, Ph.D.

Updated 2026-06-15T00:00:00.000Z17 min read · 4,512 words

Wegovy is the brand of semaglutide that is actually approved for weight loss, and it sits among the leading weight-loss medications people compare. It is the same molecule inside Ozempic, made by the same company, Novo Nordisk, but it is dosed higher, approved for a different job, and priced and covered under a completely different set of rules. If you have ever wondered why your insurance covers a relative's Ozempic for diabetes but refuses to touch your Wegovy for weight, the answer is in that distinction, and it is the whole point of this page.

This is the brand and market hub for Wegovy, written for the weight-management question specifically. It answers what people search for before they start: who qualifies by BMI, what Wegovy actually costs and why coverage is so often the hard part, the 2.4 mg dose and the brand-new oral 25 mg pill, the heart-protection news from the SELECT trial, and how Wegovy differs from Ozempic in plain terms. For the underlying science of the molecule, such as how semaglutide signals in the body and the full side-effect playbook, we keep things brief and point you to the semaglutide molecule guide. The goal here is one clear map of Wegovy as a weight-loss product.

Key Takeaways

Wegovy is the weight-management brand of semaglutide, FDA-approved on June 4, 2021 for chronic weight management, the first new obesity drug approval since 2014 (FDA, 2021).

It works at a higher top dose than Ozempic, 2.4 mg once weekly, reached by stepping up slowly over about 16 weeks, and in the STEP 1 trial people lost a mean of 14.9% of body weight at 68 weeks (NEJM, 2021).

Wegovy now also reduces cardiovascular risk. In March 2024 the FDA approved it to cut the risk of heart attack, stroke, and cardiovascular death in adults with heart disease plus obesity, based on the SELECT trial's roughly 20% reduction in major events (FDA, 2024).

An oral Wegovy pill was approved in December 2025, a once-daily 25 mg tablet and the first oral GLP-1 for weight loss, which lost about 16.6% of body weight in its OASIS 4 trial (Novo Nordisk, 2025).

Coverage is the catch. Medicare is barred by law from covering any drug used only for weight loss, which is exactly the use Wegovy is approved for, so most weight-loss patients pay cash unless a heart-risk indication applies (KFF, 2025).

The cash price has dropped sharply. Novo Nordisk's self-pay price is now about $349 a month standard, with a limited-time $199 introductory offer on the two lowest doses, far below the roughly $1,349 list price (NovoCare, 2026).

Who qualifies for Wegovy?

You can be prescribed Wegovy as an adult with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, and adolescents aged 12 and older qualify at the 95th BMI percentile or above. Wegovy is meant for long-term weight management, not a quick reset.

The eligibility rules are written into the FDA-approved label, and they are about more than the number on the scale. For adults, the two doors in are a BMI of 30 (the clinical definition of obesity) on its own, or a BMI of 27 (the overweight range) when paired with a weight-related health problem (FDA, 2025). In December 2022 the label was expanded to include adolescents aged 12 and older with obesity, making Wegovy one of the few weight medicines approved for that age group (Novo Nordisk, 2025).

A clinician also screens you out where the boxed warning applies. Because animal studies linked semaglutide to thyroid C-cell tumors, Wegovy is not for people with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2 (FDA, 2025). It is also paired with a reduced-calorie diet and increased activity rather than used alone. The deeper safety profile and contraindication list live in the semaglutide side-effects guide.

A close-up of a pale-teal weight-management injection pen lying on a clean white surface beside a soft fabric tape measure, calm morning light, no text or logos.

Citation capsule. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and in adolescents aged 12 and older with obesity, used alongside a reduced-calorie diet and increased physical activity. Source: FDA Wegovy Prescribing Information, 2025.

How much weight do people lose on Wegovy?

In its main trial, people on Wegovy lost a mean of about 14.9% of their body weight over 68 weeks, far more than the diabetes-dosed Ozempic typically produces, which is the whole reason a separate higher-dose brand exists. Results vary widely from person to person.

The headline number comes from STEP 1, the pivotal trial published in 2021. Adults with obesity who took semaglutide 2.4 mg weekly lost a mean of 14.9% of their body weight at 68 weeks, compared with 2.4% on placebo, and most participants lost at least 5% (NEJM, 2021). That degree of loss is what set Wegovy apart from earlier weight drugs and from the lower Ozempic doses.

The mechanism is the same GLP-1 effect that makes Ozempic work, just pushed to a higher dose: semaglutide mimics a gut hormone that slows stomach emptying and reduces appetite, so people eat less without constant willpower. We keep the pharmacology brief here because it belongs to the molecule, not the brand. For how semaglutide signals at the receptor and how that drives appetite changes, see the semaglutide molecule guide and how peptides work in the body.

How is Wegovy dosed, and what is the 2.4 mg schedule?

Wegovy is a once-weekly injection that climbs through five steps over about 16 weeks, 0.25, 0.5, 1.0, 1.7, and finally the 2.4 mg maintenance dose, with each step lasting roughly four weeks to limit nausea. The slow climb is the price of tolerating a high dose.

This titration is the practical heart of the brand. You do not start at 2.4 mg; you build up to it. The starting 0.25 mg dose is deliberately too low to do much for weight, and its only job is to let your gut adjust before the dose rises (FDA, 2025). This is the same titration logic as Ozempic, but Wegovy goes higher, to 2.4 mg rather than stopping at 1 or 2 mg, and Novo Nordisk has since added an even higher 7.2 mg maintenance option. The step-up schedule is shown below.

Wegovy climbs to a higher maintenance dose than Ozempic, which is the core brand difference.

The full week-by-week schedule, what to do about a missed dose, and how to manage the digestive side effects during titration live in the semaglutide dosing chart, so we keep this brand-level. The injection technique itself is covered in the peptide injection guide.

How much does Wegovy cost in 2026?

Wegovy's list price is roughly $1,349 a month, but almost nobody pays that; Novo Nordisk's cash-pay price is now about $349 a month standard, with a limited-time $199 introductory offer on the two lowest doses, and people with commercial insurance that covers it can pay as little as about $25. What you pay turns almost entirely on whether your plan covers weight loss at all.

Several different prices get tangled together, so it helps to separate them:

List price (WAC): about $1,349 per month, the sticker price set by Novo Nordisk and rarely what anyone actually pays (NovoCare, 2026).
Cash-pay (NovoCare self-pay): now about $349 a month standard for the pen, with a limited-time $199 a month introductory offer on the 0.25 and 0.5 mg starting doses, a steep cut from the $499 price that held through much of 2025 (NovoCare, 2026).
With commercial insurance plus a savings card: eligible, commercially insured patients may pay as little as about $25 a month when their plan covers Wegovy (confirm current eligibility and term limits on the official savings page).
Coming Medicare option: beginning July 1, 2026, eligible Medicare patients may access weight-loss GLP-1s at roughly $50 a month through a federal demonstration, discussed in the coverage section below (KFF, 2025).

Because these figures move and depend on eligibility and promotional windows, treat them as a 2026 snapshot rather than a quote, and confirm the live number with NovoCare. The semaglutide molecule guide tracks the full pricing and access breakdown.

Wegovy's sticker price is high, but the cash-pay price fell hard in 2026, narrowing the gap.

Is Wegovy covered by insurance or Medicare?

Coverage is the single hardest part of getting Wegovy, because it is approved for weight loss, and Medicare is barred by federal law from covering any drug used only for weight loss; many commercial plans also exclude weight-loss drugs, though that is slowly starting to change. The diagnosis on your prescription decides almost everything.

This is where Wegovy and Ozempic split most sharply. Ozempic is approved for diabetes, a condition insurers routinely cover, while Wegovy is approved for weight management, which a federal statute specifically excludes from Medicare coverage (KFF, 2025). Commercial plans are not bound by that statute, but many still decline to cover weight-loss drugs or require documentation of prior attempts, which is why so many Wegovy users end up paying cash.

There are two openings worth knowing. First, Wegovy's 2024 cardiovascular approval gives Medicare and some plans a covered reason to pay when a patient has both obesity and established heart disease, because that is a heart-risk indication rather than weight loss alone. Second, a federal demonstration called the BALANCE model, with a Medicare GLP-1 bridge beginning July 1, 2026, would let eligible Medicare and Medicaid beneficiaries access weight-loss GLP-1s for roughly $50 a month, a notable crack in the old exclusion (KFF, 2025). Until those routes apply to you, the practical rule stands: covered when there is a non-weight reason, rarely for weight alone.

Wegovy vs Ozempic: same drug, different job

Wegovy and Ozempic are the same molecule, semaglutide, made by the same company, but Wegovy is approved and dosed for weight loss at up to 2.4 mg while Ozempic is approved and dosed for type 2 diabetes at up to 2 mg, and that difference drives everything about price and coverage. They are siblings, not rivals.

People constantly ask whether they can just use one in place of the other. Pharmacologically they are interchangeable in the sense that both deliver semaglutide, which is why Ozempic became famous for off-label weight loss in the first place. But they are sold as distinct brands with distinct labels, doses, and insurance treatment, so the right choice is about indication and coverage, not the active ingredient. The table below lays out the brand-level differences.

Feature	Wegovy	Ozempic
Approved use	Chronic weight management; CV risk reduction	Type 2 diabetes; CV and kidney risk
Top dose	2.4 mg weekly (plus a 7.2 mg option)	2 mg weekly
Form	Weekly injection; new daily 25 mg pill	Weekly injection; oral form launching
Who it is for	BMI 30+, or 27+ with a condition; ages 12+	Adults with type 2 diabetes
Insurance reality	Often excluded as weight-loss; Medicare barred	Commonly covered for diabetes
Maker	Novo Nordisk	Novo Nordisk

The other comparison people weigh is against the tirzepatide brand for weight loss, covered in Zepbound vs Wegovy. Because the molecule is identical to Ozempic, the deep results-and-mechanism head-to-head belongs to the molecule layer, not here. The detailed comparison of efficacy, side effects, and switching lives in the Ozempic vs Wegovy comparison, and the brand-cost story for the diabetes side is in the Ozempic brand guide. For the underlying drug, see the semaglutide guide.

Does Wegovy protect the heart? The SELECT trial

Yes. Since March 2024, Wegovy is FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have both obesity and established heart disease, based on the SELECT trial, which found about a 20% reduction in major cardiovascular events. This made it the first weight drug approved for a heart benefit.

The evidence comes from SELECT, a large trial of more than 17,000 adults with obesity or overweight and existing cardiovascular disease but without diabetes. Wegovy cut the risk of major adverse cardiovascular events, a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke, by roughly 20% compared with placebo (NEJM, 2023). On the strength of that result, the FDA added the cardiovascular indication in March 2024 (FDA, 2024).

This matters for more than health, because a heart-risk indication can unlock coverage that weight loss alone cannot. For patients who qualify on cardiovascular grounds, Wegovy stops being a pure weight-loss drug in the eyes of an insurer and becomes a heart medicine, which some plans and Medicare will pay for. It is one of the few clean paths around the weight-loss coverage exclusion.

Is there a Wegovy pill, and how does it compare?

Yes. In December 2025 the FDA approved an oral Wegovy, a once-daily 25 mg tablet that is the first oral GLP-1 approved for weight loss, which produced about 16.6% mean weight loss in its trial, somewhat more than the injection's headline figure. It gives needle-averse patients a real option.

The oral version was approved on December 22, 2025 as the first and only oral GLP-1 for weight management in adults (Novo Nordisk, 2025). In its OASIS 4 trial, people who stayed on the 25 mg pill lost about 16.6% of their body weight over 64 weeks, with roughly one in three losing 20% or more (Novo Nordisk, 2025).

The pill is not the same as Rybelsus, an older oral semaglutide approved only for diabetes at lower doses. Oral Wegovy is a higher-dose tablet built for weight management, and like the injection it titrates up rather than starting at full strength. The exact oral titration steps should be confirmed against the current label with your clinician. Cash pricing on the pill currently starts around $149 a month for the lowest dose under a limited-time offer (NovoCare, 2026).

Is the Wegovy shortage over, and what about compounded versions?

Yes. The FDA declared the semaglutide injection shortage resolved on February 21, 2025, so Wegovy is generally available again, and that resolution also ended the legal basis for the mass-compounded copies many people had relied on. Compounded Wegovy is no longer broadly legal.

Through 2022 and into early 2025, demand for semaglutide, much of it for weight loss, outran supply, and Wegovy spent long stretches on the FDA shortage list. The agency confirmed the injectable semaglutide shortage was resolved as supply stabilized in early 2025 (FDA, 2025). With the shortage over, pharmacies can again order standard Wegovy doses, though individual stores can still have brief gaps.

The end of the shortage had a second effect. During a shortage, pharmacies are permitted to compound copies of a scarce drug, and many telehealth sellers built businesses on cheap compounded semaglutide. Once the FDA resolved the shortage in 2025, that legal basis disappeared, so broadly marketed compounded Wegovy lost its footing. Products still sold as compounded or research-use-only semaglutide are not FDA-verified for identity, dose, or sterility. For how to evaluate any peptide's paperwork, see how to vet peptide quality, and for the rules, are peptides legal.

Our take: The cash-pay price cut to about $349, and the $199 introductory offer, did more for real-world access than the end of compounding took away. If your plan will not cover Wegovy for weight loss, the honest 2026 options are the official self-pay program, a cardiovascular indication if it applies to you, or the coming Medicare demonstration, not a gray-market vial you cannot verify.

What does our community usage data show?

Within the ProtocolPlus community, semaglutide, the drug in both Wegovy and Ozempic, is one of the most-tracked compounds, and members typically finish a multi-dose vial in about three to four weeks, consistent with once-weekly use. These are usage-pattern figures from our app, labeled as community signal, not a clinical or stability claim.

In our anonymized tracking data, semaglutide accounts for a large share of activity: 38,900 logged doses from 6,224 tracking users, drawn from a global window of 27,272 unique trackers and 233,668 logged doses (data window September 2024 to June 2026). The median vial in our community runs about 26 days from first to last logged dose, clustering right around the three-to-four-week window that mirrors weekly dosing. As with all our app data, these numbers describe how people use the compound, not how long it is chemically stable.

Semaglutide is among the most-tracked compounds in our community, a usage signal that mirrors its real-world popularity.

How do you get Wegovy?

You get Wegovy with a prescription from a licensed clinician, filled at a pharmacy; you can start in person or through a reputable telehealth service, but the legitimate route always ends with genuine, pharmacy-dispensed product. There is a clear path and a risky shortcut.

The legitimate path looks like this:

See a clinician who confirms you meet the BMI criteria and screens you for the boxed-warning contraindications.
Get a prescription for Wegovy at the starting 0.25 mg dose.
Settle coverage first, checking whether your plan covers weight loss, whether a cardiovascular indication applies, or whether the cash-pay or coming Medicare option fits your budget.
Fill it at a licensed pharmacy, retail or through Novo Nordisk's NovoCare, which dispenses genuine product.
Follow the titration plan, stepping up roughly every four weeks to the 2.4 mg maintenance dose while managing side effects.

The shortcut to avoid is buying vials labeled research-use-only, compounded, or shipped from overseas sellers. With the shortage resolved, those are no longer a legal or quality-verified option, and you cannot confirm what is inside. The injection technique is covered in our peptide injection guide, and the full dosing detail in the semaglutide dosing chart.

A bright, modern pharmacy pickup counter with a clinician's hand passing a small medication carton to a patient, warm natural light, clean and professional, no readable text or logos.

Frequently Asked Questions

Adults qualify with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Adolescents aged 12 and older qualify at the 95th BMI percentile or above. A clinician also screens for thyroid-tumor history, which is a contraindication.

The bottom line

Wegovy is the weight-loss side of semaglutide: the same molecule as Ozempic, dosed higher to 2.4 mg and approved specifically for chronic weight management, with a 14.9% average weight loss in trials, a 2024 heart-risk approval from the SELECT trial, and a brand-new oral 25 mg pill. The molecule is settled; what makes Wegovy its own story is who it is for and how it is paid for.

If you take away one idea, make it the coverage gap. Because Wegovy is approved for weight loss, the use Medicare is legally barred from covering, the practical decision is almost always about money: whether your plan covers it, whether a cardiovascular indication applies, whether the new $349 cash-pay price works, or whether the coming Medicare demonstration reaches you. Match the brand to your real situation, confirm coverage before you start, and get genuine product through a licensed pharmacy. From here, the natural next steps are the semaglutide molecule guide and the Ozempic vs Wegovy comparison. And for anything you might consider, talk to a qualified clinician first.

Sources

FDA. "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014." 2021. Retrieved 2026-06-15. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
FDA. "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." 2024. Retrieved 2026-06-15. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine, 2023. Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FDA. "Wegovy (semaglutide) injection, Prescribing Information." 2025. Retrieved 2026-06-15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
Novo Nordisk / PR Newswire. "FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults." 2025. Retrieved 2026-06-15. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
Novo Nordisk. "Wegovy Cost & Coverage Information." NovoCare / wegovy.com, 2026. Retrieved 2026-06-15. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
Novo Nordisk. "Wegovy for Adolescents." 2025. Retrieved 2026-06-15. https://www.wegovy.com/about-wegovy/wegovy-for-adolescents.html
KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge." 2025. Retrieved 2026-06-15. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
FDA. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." 2025. Retrieved 2026-06-15. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize